Silvina Ayelén Casares Diaz1, Martín Milanesio2, Enzo Marcelo Amelia3, Emanuel José Saad4, Luciana Guanchiale5, Juan Manuel Alomar6. 1. Hospital Privado Universitario de Córdoba. silvi.casaresdiaz@gmail.com. 2. Hospital Privado Universitario de Córdoba. mmilanesio5@gmail.com. 3. Hospital Privado Universitario de Córdoba. enzomarceloamelia@gmail.com. 4. Hospital Privado universitario de Córdoba. emanuelsaad@hotmail.com. 5. Hospital Privado Universitario de Córdoba. lucianaguanchiale@hotmail.com. 6. Hospital Privado Universitario de Córdoba. juan.alomar@hospitalprivado.com.ar.
Abstract
Introduction: Hemophagocytic lymphohistiocytosis (HHL), a severe hyperinflammatory syndrome caused by aberrant activation of macrophages and cytotoxic T cells, is clinically manifested as a febrile onset along with cytopenias, high ferritin serum level and splenomegaly. In adult patients, secondary causes of it should be looked for, such as autoimmune and infectious diseases and neoplasms. Prompt initiation of treatment is important due to the high mortality of this syndrome. Methods: A case of a 53-year-old patient diagnosed with HHL associated with T-cell lymphoma is presented as a sudden onset of several symptoms and signs of HHL, along with infectious complications. Results: Results: Once the diagnosis of HHL was made, treatment with Etoposide and Dexamethasone was started, and with the diagnosis of T-cell lymphoma established, chemotherapy treatment with a CHOEP scheme was started, with a favorable initial evolution. Main conclusion: As HHL is a rare entity associated with high mortality, initial suspicion must be high when facing an acute onset of fever, cytopenia and splenomegaly. Nonetheless, diagnosing HHL is challenging and often appear superimposed on multiple infectious diseases. The early initiation of treatmbent is important given the high mortality of this pathology Universidad Nacional de Córdoba
Introduction: Hemophagocytic lymphohistiocytosis (HHL), a severe hyperinflammatory syndrome caused by aberrant activation of macrophages and cytotoxic T cells, is clinically manifested as a febrile onset along with cytopenias, high ferritin serum level and splenomegaly. In adult patients, secondary causes of it should be looked for, such as autoimmune and infectious diseases and neoplasms. Prompt initiation of treatment is important due to the high mortality of this syndrome. Methods: A case of a 53-year-old patient diagnosed with HHL associated with T-cell lymphoma is presented as a sudden onset of several symptoms and signs of HHL, along with infectious complications. Results: Results: Once the diagnosis of HHL was made, treatment with Etoposide and Dexamethasone was started, and with the diagnosis of T-cell lymphoma established, chemotherapy treatment with a CHOEP scheme was started, with a favorable initial evolution. Main conclusion: As HHL is a rare entity associated with high mortality, initial suspicion must be high when facing an acute onset of fever, cytopenia and splenomegaly. Nonetheless, diagnosing HHL is challenging and often appear superimposed on multiple infectious diseases. The early initiation of treatmbent is important given the high mortality of this pathology Universidad Nacional de Córdoba
Authors: Jan-Inge Henter; Annacarin Horne; Maurizio Aricó; R Maarten Egeler; Alexandra H Filipovich; Shinsaku Imashuku; Stephan Ladisch; Ken McClain; David Webb; Jacek Winiarski; Gritta Janka Journal: Pediatr Blood Cancer Date: 2007-02 Impact factor: 3.167
Authors: María Adoración Martín-Gómez; Mercedes Caba-Molina; María José Viciana-Martínez-Lage; Rosa Ortega-Salas; Alicia Sánchez-Crespo; Manuel Jesús Soriano-Pérez; Mercedes Gómez-Morales Journal: Biomedica Date: 2018-12-01 Impact factor: 0.935
Authors: Dylan E Lee; M Estela Martinez-Escala; Linda M Serrano; Xiaolong A Zhou; Jason B Kaplan; Barbara Pro; Jaehyuk Choi; Joan Guitart Journal: JAMA Dermatol Date: 2018-07-01 Impact factor: 10.282
Authors: Michael B Jordan; Carl E Allen; Jay Greenberg; Michael Henry; Michelle L Hermiston; Ashish Kumar; Melissa Hines; Olive Eckstein; Stephan Ladisch; Kim E Nichols; Carlos Rodriguez-Galindo; Birte Wistinghausen; Kenneth L McClain Journal: Pediatr Blood Cancer Date: 2019-07-24 Impact factor: 3.167